Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial

Patient-reported outcome (PRO) metrics, including health-related quality of life (HRQoL), are becoming an increasingly important element of clinical trials, including radiotherapy trials.

Source: Radiotherapy and Oncology - April 23, 2024 Category: Radiology Authors: Saskia A. Cooke, Jos é S.A. Belderbos, Bart Reymen, Maarten Lambrecht, Gitte Fredberg Persson, Corinne Faivre-Finn, Edith M.T. Dieleman, Judi N.A. van Diessen, Jan-Jakob Sonke, Dirk de Ruysscher Tags: Original Article Source Type: research